213 related articles for article (PubMed ID: 31669808)
21. Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.
Beslon V; Moreau P; Maruani A; Maisonneuve H; Giraudeau B; Fournier JP
J Gen Intern Med; 2018 Mar; 33(3):358-366. PubMed ID: 29204974
[TBL] [Abstract][Full Text] [Related]
22. Ultrasound in gout: a useful tool for following urate-lowering therapy.
Ottaviani S; Gill G; Aubrun A; Palazzo E; Meyer O; Dieudé P
Joint Bone Spine; 2015 Jan; 82(1):42-4. PubMed ID: 25543275
[TBL] [Abstract][Full Text] [Related]
23. Treat-to-Target urate-lowering therapy in primary gout patients: A real-world retrospective study at a dedicated gout clinic in China.
Bai XS; Wang M; Zhao XD; Cui LL; He YW; Wang C; Li XD; Qu XJ; Sun MS; Li CG
Technol Health Care; 2021; 29(1):121-131. PubMed ID: 32444582
[TBL] [Abstract][Full Text] [Related]
24. Temporal evolution of urate crystal deposition over articular cartilage after successful urate-lowering therapy in patients with gout: An ultrasonographic perspective.
Das S; Goswami RP; Ghosh A; Ghosh P; Lahiri D; Basu K
Mod Rheumatol; 2017 May; 27(3):518-523. PubMed ID: 27492663
[TBL] [Abstract][Full Text] [Related]
25. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
26. Changes in Tophus Composition During Urate-Lowering Therapy: A Dual-Energy Computed Tomography Study.
Chen L; Gamble GD; Horne A; Drake J; Doyle AJ; Uhlig T; Stamp LK; Dalbeth N
Arthritis Care Res (Hoboken); 2023 Sep; 75(9):1949-1954. PubMed ID: 36594401
[TBL] [Abstract][Full Text] [Related]
27. Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study.
Jatuworapruk K; Satpanich P; Robinson PC; Grainger R
J Rheumatol; 2023 Apr; 50(4):556-563. PubMed ID: 36379566
[TBL] [Abstract][Full Text] [Related]
28. How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials.
Stewart S; Tallon A; Taylor WJ; Gaffo A; Dalbeth N
Semin Arthritis Rheum; 2020 Apr; 50(2):303-313. PubMed ID: 31796212
[TBL] [Abstract][Full Text] [Related]
29. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
Yamanaka H; Tamaki S; Ide Y; Kim H; Inoue K; Sugimoto M; Hidaka Y; Taniguchi A; Fujimori S; Yamamoto T
Ann Rheum Dis; 2018 Feb; 77(2):270-276. PubMed ID: 29102957
[TBL] [Abstract][Full Text] [Related]
30. Zhengqing fengtongning sustained-release tablets prevents gout flares in the process of ULT: A randomized, positive control, double-blind, double-simulation, multicenter trial.
Jia E; Hu S; Geng H; Zhu H; Xie J; Xiao Y; Jiang Y; Xiao M; Zhang J
Medicine (Baltimore); 2022 May; 101(18):e29199. PubMed ID: 35550468
[TBL] [Abstract][Full Text] [Related]
31. Ultrasonography in the prediction of gout flares: a 12-month prospective observational study.
Cipolletta E; Abhishek A; Di Battista J; Grassi W; Filippucci E
Rheumatology (Oxford); 2023 Mar; 62(3):1108-1116. PubMed ID: 35920773
[TBL] [Abstract][Full Text] [Related]
32. Patient and clinical characteristics associated with gout flares in an integrated healthcare system.
Rashid N; Levy GD; Wu YL; Zheng C; Koblick R; Cheetham TC
Rheumatol Int; 2015 Nov; 35(11):1799-807. PubMed ID: 25991397
[TBL] [Abstract][Full Text] [Related]
33. [Gout management: an update].
Ankli B; Krähenbühl S
Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
[TBL] [Abstract][Full Text] [Related]
34. 12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target.
Uhlig T; Karoliussen LF; Sexton J; Borgen T; Haavardsholm EA; Kvien TK; Hammer HB
RMD Open; 2021 Mar; 7(1):. PubMed ID: 33782189
[TBL] [Abstract][Full Text] [Related]
35. COVID-19 Vaccination and Gout Flare Risk in Patients With Infrequent or Frequent Flares: A Prospective Cohort Study.
He Y; Xue X; Dalbeth N; Terkeltaub R; Chen Y; Yan F; Pang L; Li X; Yuan X; Cheng X; Li C; Sun M
Arthritis Care Res (Hoboken); 2024 Jan; 76(1):131-139. PubMed ID: 37553607
[TBL] [Abstract][Full Text] [Related]
36. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy.
Becker MA; MacDonald PA; Hunt BJ; Lademacher C; Joseph-Ridge N
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):585-91. PubMed ID: 18600509
[TBL] [Abstract][Full Text] [Related]
37. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
Mandell BF; Yeo AE; Lipsky PE
Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
[TBL] [Abstract][Full Text] [Related]
38. Development of a prediction model for inpatient gout flares in people with comorbid gout.
Jatuworapruk K; Grainger R; Dalbeth N; Taylor WJ
Ann Rheum Dis; 2020 Mar; 79(3):418-423. PubMed ID: 31811060
[TBL] [Abstract][Full Text] [Related]
39. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
[TBL] [Abstract][Full Text] [Related]
40. Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
Latourte A; Bardin T; Clerson P; Ea HK; Flipo RM; Richette P
Arthritis Care Res (Hoboken); 2018 Jun; 70(6):918-924. PubMed ID: 28834411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
